Status:
COMPLETED
Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study
Lead Sponsor:
CHU de Reims
Conditions:
Amikacin Treatment
Eligibility:
All Genders
18+ years
Brief Summary
Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care ...
Detailed Description
The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.
Eligibility Criteria
Inclusion
- inclusion criteria :
- patients in intensive care
- patients on extrarenal replacement
- patients with Amikacin treatment
- patients accepting to participate in the study
- exclusion criteria :
- patients less than 18 years old
- pregnant women
- patients with Amikacin treatment in the previous 7 days
Exclusion
Key Trial Info
Start Date :
May 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 16 2022
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT04322019
Start Date
May 25 2020
End Date
May 16 2022
Last Update
June 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France